

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1: Name and Address of Reporting Issuer

Sire Bioscience Inc. (the “**Company**”)
2500 Meadowpine Blvd, Unit 202
Mississauga, ON L5N 6C4

Item 2: Date of Material Change

March 31, 2021.

Item 3: News Release

A news release was issued and disseminated on March 29, 2021 and filed on SEDAR (www.sedar.com).

Item 4: Summary of Material Changes

The Company announced the issuance of common shares (the “**Shares**”) for services. See Item 5 for full details.

Item 5: Full Description of Material Change

The Company announced that pursuant to a consulting agreement (the “**Agreement**”) entered into with a consultant (the “**Consultant**”) and subject to the approval of the CNSX Markets Inc., it proposes to issue 59,524 Shares of the Company at a deemed price of \$0.42 per Share for past services provided by the Consultant.

Pursuant to the Agreement, the Company agreed to remunerate the Consultant \$25,000, exclusive of HST, per quarter, payable in Shares of the Company. The deemed value of the Shares will be determined by the closing market price on the day proceeding the issuance of the Shares. The issuance of 59,524 Shares represents the first of four payments to the Consultant.

All Shares issued pursuant to the Agreement will be subject to a mandatory four month hold period from the dates of issuances.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

None.

Item 8: Executive Officer

Brian Polla, CEO and COO
T: 416.669.9392
E: ir@sirebioscience.com

Item 9: Date of Report

March 31, 2021.